Welcome to our dedicated page for Privia Health Group SEC filings (Ticker: PRVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Privia Health Group, Inc. files SEC reports that document its physician enablement business, operating results, governance and public-company capital structure. Its 8-K reports commonly furnish quarterly and annual financial releases, including revenue, care margin, platform contribution, adjusted EBITDA, guidance, value-based risk arrangements and provider-network growth.
Proxy and other material-event filings cover board and committee governance, shareholder voting matters, material agreements, risk factors, regulatory disclosures and other updates tied to a Delaware corporation listed on Nasdaq under PRVA.
Privia Health Group, Inc. Chief Executive Officer Parth Mehrotra reported a sale of 26,509 shares of common stock on March 16, 2026 at an average price of $22.11 per share. According to the disclosure, this was a nondiscretionary sale to cover tax withholding obligations related to vesting and settlement of performance stock units. After the transaction, Mehrotra directly holds 555,443 shares of Privia Health Group common stock.
Privia Health Group EVP & CFO David Mountcastle reported routine share dispositions tied to tax withholding. On March 13, 2026, he sold 6,565 shares of common stock at $21.52 per share, and on March 12, 2026, he sold 6,453 shares at $21.90 per share in open-market transactions. A footnote explains these were nondiscretionary “sell to cover” transactions required to satisfy tax withholding obligations from the vesting and settlement of performance stock units. After these transactions, he held 226,804 shares directly and 8,695 shares indirectly through his spouse.
Privia Health Group, Inc. Chief Executive Officer Parth Mehrotra reported two transactions involving company common stock. On March 12, he sold 26,763 shares at $21.90 per share, followed by a sale of 27,229 shares at $21.52 per share on March 13. A footnote explains these sales were nondiscretionary sell-to-cover transactions required to satisfy tax withholding obligations tied to the vesting and settlement of performance stock units, rather than elective portfolio moves. After the second transaction, Mehrotra directly held 581,952 shares of Privia Health Group common stock.
Parth Mehrotra reported planned sales of Common Stock. The Form 144 lists sales on 03/06/2026 (21,440 shares, $496,357.44), 03/09/2026 (41,999 shares, $960,197.55), 03/10/2026 (21,097 shares, $479,144.34), 03/12/2026 (26,763 shares, $586,096.32), and 03/13/2026 (27,229 shares, $586,096.06).
The filing also shows a restricted stock vesting on 03/13/2026 of 26,509 shares reported as compensation. Broker information lists Fidelity Brokerage Services LLC for transactions on 03/16/2026.
PRVA notice under Rule 144 reporting planned/resumed sales of Common Stock and recent dispositions by an affiliated holder. The filing lists a restricted stock vesting delivery of 6,391 shares on 03/13/2026 as compensation and multiple sales by David Mountcastle during Feb–Mar 2026 with dated share quantities and proceeds.
PRVA issuer notice: a Form 144 reports an intended sale of 27,229 shares of common stock tied to restricted stock vesting on 03/12/2026.
Parth Mehrotra reported multiple cash sales during March 2026: 21,440 shares on 03/06/2026, 41,999 on 03/09/2026, 21,097 on 03/10/2026, and 26,763 on 03/12/2026.
PRVA reported insider sales by David Mountcastle. The filing lists multiple dispositions of Common Stock under Rule 144 on 02/26/2026 (5,361 shares, $134,030.87), 02/27/2026 (7,697 shares, $192,798.08), 03/06/2026 (5,177 shares, $119,852.73), 03/09/2026 (5,829 shares, $133,158.26), and 03/12/2026 (6,453 shares, $141,317.47).
Privia Health Group Chief Executive Officer Parth Mehrotra reported a mix of stock awards and a planned share sale. He received 171,904 shares of common stock as a grant or award on March 11, 2026, and 141,342 shares as a grant or award on March 10, 2026, both at no cash cost to him.
On March 10, 2026, he sold 21,097 shares of common stock at a weighted average price of $22.71 per share, with individual trade prices ranging from $22.27 to $23.23, under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly held 635,944 shares of Privia Health Group common stock.
Fargis Edward C reported acquisition or exercise transactions in this Form 4 filing.
Privia Health Group, Inc. executive vice president and general counsel Edward C. Fargis reported receiving a grant of 28,268 shares of common stock in the form of restricted stock units at no cash cost per share. These units were awarded under the 2021 Omnibus Incentive Plan.
The restricted stock units will vest in substantially equal annual installments on the first, second and third anniversaries of the grant date, generally contingent on continued service through each vesting date. Following this grant, Fargis directly holds 111,979 shares of common stock.
Mountcastle David reported acquisition or exercise transactions in this Form 4 filing.
Privia Health Group EVP & CFO David Mountcastle reported equity awards of common stock. He received 42,584 shares and 35,335 shares of common stock at a price of $0.00 per share as compensation grants, increasing his direct holdings to 239,822 shares.
Footnotes explain these shares relate to restricted stock units under the 2021 Omnibus Incentive Plan that vest in three equal annual installments and to performance stock units granted on May 9, 2023 for the 2023–2025 performance period that have now vested and been distributed. An additional 8,695 shares are held indirectly by his spouse.